Sequent Scientific Limited Overview
Pro stress-test →Sequent Scientific Limited is India's leading animal health company, ranked among the top 20 globally, with operations across 90+ countries. The company provides integrated animal health solutions including Active Pharmaceutical Ingredients (APIs), finished dosage formulations (FDFs), and analytical services with manufacturing facilities in India, Spain, Brazil, and Turkey.
Strategic Profile
Pro stress-test →Sequent operates with significant regulatory approvals (USFDA, EUGMP, WHO, TGA) and maintains a strong global footprint through its Alivira brand. Recently completed a transformational amalgamation with Viyash Lifesciences (effective December 2025), appointing new leadership focused on API business expansion and long-term sustainability.
Competitive Landscape
Pro stress-test →Sequent competes in the fragmented global animal health market against major international players. Its competitive advantage lies in API manufacturing expertise, regulatory approvals, and established distribution in 90+ countries. The company positions itself as an integrated solution provider combining APIs, FDFs, and analytical services.
Industry Context
Sequent Scientific Limited operates in Animal Health / Veterinary Pharmaceuticals.
Key facts
Founded: 1985 · Headquarters: Hyderabad, India · Revenue: ₹13.69 billion · Market cap: ₹9,431 Cr (as of February 16, 2026)